Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors
| Autor: | John Forsayeth, Daryl C. Drummond, Piotr Hadaczek, Mitchel S. Berger, Janine Beyer, Mark E. Hayes, Krystof S. Bankiewicz, Charles O. Noble, Michal T. Krauze, John W. Park, Dmitri B. Kirpotin |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Drug
Oncology medicine.medical_specialty media_common.quotation_subject Biomedical Engineering Brain tumor Medicine (miscellaneous) Bioengineering Development Pharmacology Irinotecan Pharmacokinetics health services administration Internal medicine Glioma Mean Survival Time medicine Animals General Materials Science neoplasms media_common Antitumor activity business.industry Brain Neoplasms medicine.disease Antineoplastic Agents Phytogenic digestive system diseases Nanostructures Rats stomatognathic diseases Drug delivery Liposomes Camptothecin business therapeutics medicine.drug |
| Zdroj: | Nanomedicine (London, England). 9(14) |
| ISSN: | 1748-6963 |
| Popis: | Aim: We sought to evaluate nanoliposomal irinotecan as an intravenous treatment in an orthotopic brain tumor model. Materials & methods: Nanoliposomal irinotecan was administered intravenously in the intracranial U87MG brain tumor model in mice, and irinotecan and SN-38 levels were analyzed in malignant and normal tissues. Therapy studies were performed in comparison to free irinotecan and control treatments. Results: Tissue analysis demonstrated favorable properties for nanoliposomal irinotecan, including a 10.9-fold increase in tumor AUC for drug compared with free irinotecan and 35-fold selectivity for tumor versus normal tissue exposure. As a therapy for orthotopic brain tumors, nanoliposomal irinotecan showed a mean survival time of 54.2 versus 29.5 days for free irinotecan. A total of 33% of the animals receiving nanoliposomal irinotecan showed no residual tumor by study end compared with no survivors in the other groups. Conclusion: Nanoliposomal irinotecan administered systemically provides significant pharmacologic advantages and may be an efficacious therapy for brain tumors. Original submitted 1 March 2013; Revised submitted 10 October 2013 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|